Why Is CELLEBRITE DI LTD A (CLBT) Stock Down Today?

Cellebrite DI Ltd. (CLBT) stock fell 29.18% to $10.80 on Aug. 13, 2026, following a significant earnings miss and a cut to full-year revenue guidance. The digital forensics firm cited delays in large transactions and increased competition for cloud and AI procurement as key factors. The stock’s sharp decline came amid leadership changes and a broader selloff in the information technology sector.

What Happened

Cellebrite reported second-quarter results that fell short of expectations, prompting a downward revision to its 2026 revenue guidance. The company announced a leadership change and outlined slower deal timing as contributing to the underperformance. TD Cowen cut its price target for CLBT to $15 following the quarter’s results. Meanwhile, Kaplan Fox Kilsheimer LLP alerted investors to an ongoing investigation into potential securities law violations involving the company. The Motley Fool reported that the stock’s drop was tied to these developments, as well as broader investor concerns over AI spending and share dilution. The stock’s selloff was also highlighted as a 33% post-earnings drop by Seeking Alpha, though some analysts suggested it might be an overreaction.

What The Data Shows

The stock has fallen 33.8% over the last eight sessions, moving from $15.78 to $10.45. Recent insider transactions show three executives, CEO Hogan Thomas E., CMO Gee David Nicholas, and Global Chief Revenue Officer Jewell Marcus, selling shares on Aug. 12. Over the past 90 days, insiders have sold 7 times, totaling $4.7 million. Unusual options activity included three notable prints, with $1.2 million in call premiums. The stock currently trades within its 52-week range of $11.02 to $19.98 and has a market cap of $3.9 billion.

What To Watch

Cellebrite has not scheduled additional earnings in the near term. Investors should monitor coverage breadth and any further developments from the ongoing securities investigation or guidance revisions.